SCHEDULE: Jeremy M. Levin Discloses 4.5% Stake in Ovid Therapeutics
Beneficial Ownership Filing
Jeremy M. Levin has reported beneficial ownership of 8,551,502 shares, representing 4.5% of Ovid Therapeutics Inc.'s common stock as of March 31, 2026.
Summary
- Jeremy M. Levin has filed a Schedule 13G, indicating beneficial ownership of 8,551,502 shares of Ovid Therapeutics Inc. common stock.
- This holding represents 4.5% of the total outstanding shares as of March 31, 2026.
- The reported shares include directly held shares, shares held by Divo Holdings, LLC, shares issuable upon exercise of Series B warrants, and shares issuable upon exercise of stock options within 60 days of March 31, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance information.
Positives
- Jeremy M. Levin maintains a significant stake in Ovid Therapeutics, indicating continued confidence or investment.
- The filing details the composition of the beneficial ownership, providing transparency on various shareholding mechanisms.
Risks
- The filing does not explicitly mention any risks.
- Potential risks associated with Ovid Therapeutics' business operations, drug development pipeline, or market conditions are not detailed in this specific filing.
Future Outlook
No specific future outlook or guidance is provided in this Schedule 13G filing, as it pertains to ownership disclosure.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant beneficial ownership changes and do not typically contain operational or strategic commentary. This filing confirms Jeremy M. Levin's substantial interest in Ovid Therapeutics, a biotechnology company.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding a significant shareholder's holdings, which can be relevant for understanding the ownership structure.
- Management and Board: Confirms the continued involvement and investment of a key individual in the company.
Next Steps
- No specific next steps are outlined in this ownership disclosure filing.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of Event Which Requires Filing of this Statement |
| 05/12/2026 | Date Ovid Therapeutics' Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 was filed. |
| 05/14/2026 | Date of Certification and Signature on Schedule 13G |
Keywords
Ovid Therapeutics, Schedule 13G, Jeremy M. Levin, Beneficial Ownership, Common Stock, SEC Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.